QTTB
VENTE TOTALE: 9 845 titres (~163 033,20 $ US)
- Insiders
- Morrison Jodie Pope
- Total bought
- —
- Total sold
- $163,033
- Last activity
- 2026-08-25
- Last synced
-
2026-08-31 10:14:36
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-30
QTTB presents a compelling financial turnaround story with strong liquidity (85) and improving fundamentals (75), but the weak catalyst score (35) and low catalyst confidence (0.45) significantly temper the overall…
The first sentence of the analysis written for QTTB on 2026-08-30 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 100.0% | 0.0% | 100.0% | 100.0% | 0.0% | |
| Ebit Margin | 57.5% | 0.0% | 725.5% | -589.8% | 0.0% | |
| Ebitda Margin | 58.3% | 0.0% | 718.0% | -584.2% | 0.0% | |
| Operating Profit Margin | 31.5% | 0.0% | 725.5% | -589.8% | 0.0% | |
| Pretax Profit Margin | 55.5% | 0.0% | 803.3% | -642.7% | 0.0% | |
| Continuous Operations Profit Margin | 55.5% | 0.0% | 808.0% | -643.6% | 0.0% | |
| Net Profit Margin | 55.5% | 0.0% | 808.0% | -643.6% | 0.0% | |
| Bottom Line Profit Margin | 55.5% | 0.0% | 808.0% | -643.6% | 0.0% | |
| Current Ratio | 4.852 | 4.973 | 2.035 | 7.709 | 11.141 | |
| Quick Ratio | 4.852 | 4.973 | 2.035 | 7.709 | 11.141 | |
| Solvency Ratio | 1.529 | -0.545 | -0.232 | -0.823 | -0.892 | |
| Cash Ratio | 4.257 | 4.735 | 1.816 | 1.439 | 6.292 | |
| Price To Earnings Ratio | 1.372 | -0.672 | -2.426 | -6.318 | -20.800 | |
| Price To Earnings Growth Ratio | -0.009 | -0.050 | -0.095 | -0.452 | 0.222 | |
| Forward Price To Earnings Growth Ratio | -0.009 | -0.050 | -0.095 | -0.452 | 0.222 | |
| Price To Earnings Diluted Ratio | 1.372 | -0.523 | -2.426 | -6.318 | -20.800 | |
| Price To Earnings Diluted Growth Ratio | -0.010 | -0.011 | -0.095 | -0.452 | 0.222 | |
| Price To Book Ratio | 0.972 | 5.650 | -0.713 | 1.520 | 4.607 | |
| Price To Sales Ratio | 0.760 | 0.000 | -19.622 | 40.680 | 0.000 | |
| Price To Free Cash Flow Ratio | -1.217 | -0.473 | -6.986 | -20.128 | -6.970 | |
| Price To Operating Cash Flow Ratio | -1.217 | -0.474 | -6.988 | -24.693 | -7.122 | |
| Debt To Assets Ratio | 0.248 | 0.205 | 1.080 | 0.130 | 0.113 | |
| Debt To Equity Ratio | 0.365 | 3.331 | -0.278 | 0.168 | 0.141 | |
| Debt To Capital Ratio | 0.268 | 0.769 | -0.385 | 0.144 | 0.124 | |
| Long Term Debt To Capital Ratio | 0.076 | 0.627 | -0.309 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.470 | 16.270 | -0.257 | 1.290 | 1.248 | |
| Working Capital Turnover Ratio | 0.985 | 0.000 | -0.077 | 0.040 | 0.000 | |
| Operating Cash Flow Ratio | -2.956 | -4.113 | -1.324 | -0.464 | -6.371 | |
| Operating Cash Flow Sales Ratio | -0.624 | 0.000 | 2.808 | -1.647 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.001 | 1.000 | 1.227 | 1.022 | |
| Debt Service Coverage Ratio | 3.900 | -10.608 | -54.754 | -24.931 | -151.191 | |
| Interest Coverage Ratio | 15.365 | -60.093 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -4.842 | -21.865 | -21.272 | -7.019 | -446.142 | |
| Operating Cash Flow Coverage Ratio | -2.186 | -3.583 | -0.367 | -0.366 | -4.586 | |
| Capital Expenditure Coverage Ratio | 0.000 | -902.867 | -3,735.400 | -4.409 | -45.806 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | -902.867 | -3,735.400 | -4.409 | -45.806 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 0.252 | 0.607 | -3.261 | -6.859 | -19.025 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 100.0% | ▲100.0% | ▲40.0% |
| Ebit Margin | 57.5% | ▲57.5% | ▲18.9% |
| Ebitda Margin | 58.3% | ▲58.3% | ▲19.9% |
| Operating Profit Margin | 31.4% | ▲31.4% | ▼-2.0% |
| Pretax Profit Margin | 55.5% | ▲55.5% | ▲12.3% |
| Continuous Operations Profit Margin | 55.5% | ▲55.5% | ▲11.5% |
| Net Profit Margin | 55.5% | ▲55.5% | ▲11.5% |
| Bottom Line Profit Margin | 55.5% | ▲55.5% | ▲11.5% |
| Current Ratio | 4.852 | ▼-0.121 | ▼-1.290 |
| Quick Ratio | 4.852 | ▼-0.121 | ▼-1.290 |
| Solvency Ratio | 1.529 | ▲2.074 | ▲1.721 |
| Cash Ratio | 4.257 | ▼-0.478 | ▲0.549 |
| Price To Earnings Ratio | 1.372 | ▲2.044 | ▲7.141 |
| Price To Earnings Growth Ratio | -0.009 | ▲0.040 | ▲0.068 |
| Forward Price To Earnings Growth Ratio | -0.009 | ▲0.040 | ▲0.068 |
| Price To Earnings Diluted Ratio | 1.372 | ▲1.895 | ▲7.111 |
| Price To Earnings Diluted Growth Ratio | -0.010 | ▲0.001 | ▲0.059 |
| Price To Book Ratio | 0.972 | ▼-4.678 | ▼-1.435 |
| Price To Sales Ratio | 0.760 | ▲0.760 | ▼-3.603 |
| Price To Free Cash Flow Ratio | -1.218 | ▼-0.745 | ▲5.937 |
| Price To Operating Cash Flow Ratio | -1.218 | ▼-0.744 | ▲6.881 |
| Debt To Assets Ratio | 0.248 | ▲0.044 | ▼-0.107 |
| Debt To Equity Ratio | 0.365 | ▼-2.965 | ▼-0.380 |
| Debt To Capital Ratio | 0.268 | ▼-0.502 | ▲0.084 |
| Long Term Debt To Capital Ratio | 0.076 | ▼-0.551 | ▼-0.003 |
| Financial Leverage Ratio | 1.470 | ▼-14.800 | ▼-2.534 |
| Working Capital Turnover Ratio | 0.985 | ▲0.985 | ▲0.795 |
| Operating Cash Flow Ratio | -2.956 | ▲1.156 | ▲0.089 |
| Operating Cash Flow Sales Ratio | -0.624 | ▼-0.624 | ▼-0.732 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.001 | ▼-0.050 |
| Debt Service Coverage Ratio | 3.900 | ▲14.508 | ▲51.417 |
| Interest Coverage Ratio | 15.366 | ▲75.458 | ▲24.311 |
| Short Term Operating Cash Flow Coverage Ratio | -4.842 | ▲17.023 | ▲95.386 |
| Operating Cash Flow Coverage Ratio | -2.186 | ▲1.397 | ▲0.031 |
| Capital Expenditure Coverage Ratio | 0.000 | ▲902.867 | ▲937.696 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | ▲902.867 | ▲937.696 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 0.252 | ▼-0.355 | ▲5.909 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $40.8M | $32.1M | $130.5M | $270.6M | $781.6M | |
| Enterprise value | $7.9M | -$27.0M | $155.7M | $266.5M | $697.2M | |
| EV / Sales | 0.15x | 0.00x | -23.41x | 40.07x | 0.00x | |
| EV / Op. cash flow | -0.23x | 0.40x | -8.34x | -24.32x | -6.35x | |
| EV / Free cash flow | -0.23x | 0.40x | -8.34x | -19.83x | -6.22x | |
| EV / EBITDA | 0.25x | 0.61x | -3.26x | -6.86x | -19.02x | |
| Net debt / EBITDA | -1.05x | 1.33x | -0.53x | 0.10x | 2.30x | |
| Current ratio | 4.85x | 4.97x | 2.04x | 7.71x | 11.14x | |
| Income quality | -1.12x | 1.42x | 0.35x | 0.26x | 1.15x | |
| Graham number | $14 | — | — | — | — | |
| Graham net-net | $2 | -$1 | -$17 | $10 | $10 | |
| Tax burden | 100.0% | 100.0% | 100.6% | 100.1% | 101.5% | |
| Interest burden | 96.4% | 106.1% | 110.7% | 109.0% | 100.9% | |
| Working capital | $43.7M | $65.4M | $14.6M | $158.5M | $174.7M | |
| Invested capital | $49.8M | $72.5M | $22.7M | $180.1M | $192.5M | |
| Return on assets | 48.3% | -51.7% | -114.2% | -18.7% | -17.7% | |
| Operating ROA | 21.9% | -94.8% | -34.9% | -17.8% | -15.4% | |
| Return on tangible assets | 48.3% | -51.7% | -114.2% | -18.7% | -17.7% | |
| Return on equity | 71.0% | -841.1% | 29.4% | -24.1% | -22.1% | |
| Return on invested capital | 29.5% | -83.1% | -140.4% | -18.9% | -18.8% | |
| Return on capital employed | 33.5% | -87.1% | -146.5% | -19.0% | -18.9% | |
| Earnings yield | 73.0% | -148.9% | -41.2% | -15.8% | -4.8% | |
| Free cash flow yield | -82.1% | -211.4% | -14.3% | -5.0% | -14.3% | |
| Capex / Op. cash flow | 0.0% | -0.1% | -0.0% | -22.7% | -2.2% | |
| Capex / Depreciation | 0.0% | 15.4% | 1.0% | 671.6% | 25.1% | |
| Capex / Sales | 0.0% | 0.0% | -0.1% | 37.4% | 0.0% | |
| SG&A / Sales | 32.9% | 0.0% | -148.5% | 151.3% | 0.0% | |
| R&D / Sales | 35.6% | 0.0% | -477.1% | 538.5% | 0.0% | |
| Stock comp / Sales | 9.8% | 0.0% | -21.5% | 18.6% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | -41d | 58d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | -41d | 58d | 0d | |
| Cash conversion cycle | 0d | 0d | -41d | 58d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+27.4%EV / Sales n/aEV / EBITDA ▼-58.5%EV / Op. cash flow ▼-0.634Earnings yield ▲+2.219
Profitability
Return on equity ▲+9.121Return on assets ▲+1.000Return on invested capital ▲+1.125Return on capital employed ▲+1.206Operating ROA ▲+1.168Income quality ▼-2.543Tax burden -0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.121Net debt / EBITDA ▼-2.380Working capital ▼-21708000.000Invested capital ▼-22721000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-94.8%EV / Sales n/aEV / EBITDA ▲+101.3%EV / Op. cash flow ▲+6.117Earnings yield ▲+0.778
Profitability
Return on equity ▲+0.931Return on assets ▲+0.660Return on invested capital ▲+0.483Return on capital employed ▲+0.524Operating ROA ▲+0.374Income quality ▼-2.271Tax burden ▼-0.015
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-6.289Net debt / EBITDA ▼-3.357Working capital ▼-130979000.000Invested capital ▼-142759000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-17 Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High? The average of price targets set by Wall Street analysts indicates a potential upside of 182.2% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 2026-08-05 Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update -- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial findings from 52-week results to be presented at a medical conference in the second half of 2026 -- -- Patient enrollment and dosing in SIGNAL-AA Part B open-label extension (OLE) ongoing -- -- Registration-directed program evaluating bempikibart in patients with severe or very severe AA expected to initiate in 1H''2027 subject to planned regulatory discussions later this year -- -- Half-life extended fully human anti-IL-7Rα antibody, ADX-914-XL, advancing in pre-clinical development -- -- Completed $200 million public offering in July 2026 -- -- Cash and cash equivalents of $106.3 million as of June 30, 2026, combined with proceeds from July 2026 public offering, are expected to provide financial runway through Phase 3 topline results from planned registration-directed program -- WALTHAM, Mass., Aug. 5, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended June 30, 2026, and provided recent corporate updates.
- 2026-07-31 Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a Bet The consensus price target hints at an 186% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 2026-07-23 Playing The Biotech Breakout With Insiders Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCellera Biologics and Alpha Cognition stand out for insider buying, revenue growth, and high Seeking Alpha Quant Ratings. ABCL''s Phase 2 efficacy readout for ABCL635 in Q3 and ACOG''s Zunveyl sales ramp are key catalysts. Both have substantial upside per analyst targets.
- 2026-07-20 Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice Does Q32 Bio (QTTB) have what it takes to be a top stock pick for momentum investors? Let''s find out.
- 2026-07-17 Q32 Bio: Bempikibart''s Progress Keeps Me Bullish Q32 Bio''s Part B data showed meaningful hair regrowth in severe alopecia areata, including for JAK-experienced patients. Bempikibart also seems to be relatively safe, and its treatment benefits appear to last well after finishing treatment. These factors could help differentiate Bempikibart from other continuously dosed JAK inhibitors.
- 2026-07-15 Wall Street Analysts See an 80.12% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High? The consensus price target hints at an 80.1% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 2026-07-14 Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants WALTHAM, Mass., July 14, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the pricing of an underwritten public offering of 6,027,399 shares of its common stock at a public offering price of $18.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 4,931,506 shares of its common stock at a public offering price of $18.2499 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant.
- 2026-07-13 Why Q32 Bio Stock Skyrocketed Today The biotech is advancing a potential treatment for a common autoimmune disease.
- 2026-07-13 Q32 Bio: ''Strong Buy'' On Solid Bempikibart SIGNAL-AA Study Data And Catalysts Q32 Bio upgraded to "Strong Buy" after positive phase 2a SIGNAL-AA results for bempikibart in severe alopecia areata. QTTB achieved its primary efficacy endpoint, with 35.3% mean SALT score reduction and up to 40% of severe AA patients reaching SALT 20. Bempikibart''s improved safety, durable efficacy, and maintenance dosing potential position it as a first-line alternative to JAK inhibitors.